Einstein Pharma Consultancy Services / Navi Mumbai · India / Principal Consultant: Dr. Subhash Kale
Einstein Pharma Consultancy ServicesInspection-ready regulatory science. Defensible by design.
Working references
  • 21 CFR 210
  • 21 CFR 211
  • 21 CFR Part 11
  • EU GMP Annex 1
  • WHO GMP
  • Schedule M
  • ICH Q1
  • ICH Q2(R2)
  • ICH Q7
  • ICH Q8
  • ICH Q9
  • ICH Q10
  • ICH Q14
  • ICH M7
  • ICH Q3D
  • ISO 9001
  • ISO 14001
  • ISO 17025
  • ISO 17034
  • ISO 45001

Pharmaceutical regulatory & GMP consultant · Navi Mumbai, India

A finding is never
about the finding.

Independent quality, regulatory, CMC and analytical consulting for pharmaceutical manufacturers. Thirty-one years inside Indian pharmaceutical manufacturing, brought to the problem in front of you — a deficiency letter, an incident, an inspection, a submission at risk.

Discuss an engagement
31Years in pharmaceutical
manufacturing
9Indian pharmaceutical
companies
7Global collaboration
partners
7Consultancy
clients
1.0

Capabilities

Governing reference shown left
21 CFR 210/211
EU GMP
Schedule M
ICH Q9 / Q10

Quality assurance and GMP compliance

Gap assessments against the CGMP regulations that apply to your market. Quality system design and review, batch record and SOP architecture, quality risk management (ICH Q9) and pharmaceutical quality system (ICH Q10), and preparation for inspection by a regulator you have not hosted before.

WHO GMP
EU GMP
ISO 9001 / 17025
ISO 14001 / 45001

Facility, vendor and ISO standards auditing

GMP facility audits, vendor and supplier qualification audits, and ISO management-system audits, led by an ISO 9001 Lead Auditor. Preparation services cover the work before the auditor arrives: gap assessment, document readiness, mock audits and closure of findings.

ICH Q8
ICH Q3A–C
ICH Q6A

Regulatory affairs and CMC

Pharmaceutical development and QbD under ICH Q8, dossier sections, specification justification and deficiency responses. Where a query has already been raised, the response is built from what the assessor actually asked rather than from what the file happens to contain.

ICH M7
(Q)SAR
ICH Q3D

Genotoxic and elemental impurities

Impurity assessment and control strategy under ICH M7, including (Q)SAR-based toxicity prediction, nitrosamine and NDSRI risk evaluation, and elemental impurity risk assessment for raw materials, excipients and container systems under ICH Q3D.

ICH Q14
ICH Q2(R2)
USP <1225>
ISO 17025

Analytical method development and validation

HPLC and GC method development for assay, related substances, residual solvents and dissolution — stability-indicating, and managed through the lifecycle under ICH Q14. Validation protocols and reports, method transfer, and statistical review of validation data. Where a validation has been challenged, the usual finding is a missing element rather than a bad number.

NMR · MS
XRPD · Raman
FTIR · PSD

Specialty services — structural characterization

Structural characterization and evaluation of complex data from NMR, mass spectrometry, XRPD, Raman, FTIR and particle size distribution — identity confirmation, polymorph identification and impurity structure elucidation, interpreted against the regulatory question being asked.

HBEL
MACO
EMA guidance

Cleaning validation

Health-based exposure limits, MACO derivation and cleaning validation strategy for shared facilities, written to survive review rather than to satisfy a template.

HAZOP
Barrier analysis
CAPA

Incident investigation

Independent third-party investigation of process safety and quality incidents, including hazard study, barrier analysis, statutory compliance mapping and a defined CAPA set. Prepared for submission to the authority, not for internal circulation.

Warning letters
Form FDA 483

USFDA enforcement forensics

Decoding of Warning Letters and Form FDA 483 observations to the systemic failure beneath the citation, and conversion of that failure into a pre-emptive gap assessment of your own quality system.

ISO 9001
ISO 13485
ISO 45001 / 14001

Management systems

Integrated management system design and documentation across quality, medical devices, occupational health and safety, environment, and laboratory competence.

2.0

Selected engagements

Client identities withheld under engagement confidentiality
Facility setup

KRM and intermediates manufacturing facility, Boisar MIDC

Setup completed for a major synthetic key raw material (KRM) and intermediates manufacturing project — a 25,000 sq. ft. facility with associated utilities, built and systemised to ISO 9001 quality, ISO 14001 environmental and ISO 45001 occupational health and safety management systems.

Area
25,000 sq. ft., with associated facilities
Sections
Warehouse, quality control, synthetic R&D, quality assurance, production, filling, packing, labeling, cartoning, palletizing, sleeving and dispatch
Systems
ISO 9001 · ISO 14001 · ISO 45001
Outcome
Project setup completed
Analytical

Deficiencies raised against assay validation, impurities validation, residual solvents validation, polymorph identification and NMR characterization

A generic manufacturer received regulatory deficiencies across its analytical package — assay, impurities and residual solvents validation, polymorph identification and NMR characterization. Each was traced to what the assessor actually asked, and answered with data rather than re-argument.

Scope
Validation protocols and reports, characterization data, deficiency responses
Output
Statistical correction, scientific justification, response package
Outcome
All resolved successfully, in a time-bound manner, without repeat observation
Nitrosamines

NDMA, NDEA and NMBA evaluation for dossier submission

Nitrosamine risk evaluation and limit setting, with method development on GC-MS/MS and LC-MS/MS, full validation, and three-batch analysis to support dossier submission for combination tablet products.

Products
Metformin + Pioglitazone and Losartan + Hydrochlorothiazide, tested as finished combination tablets, and related products
Methods
GC-MS/MS and LC-MS/MS, developed and validated
Output
Limits, validated methods, three-batch data
Outcome
Data package for dossier submission
Feasibility

Testing laboratory ventures, GCC

Investor-grade feasibility for two proposed testing laboratories in the Gulf — one for medical devices, one general public testing. Technical scope, accreditation pathway and full financial models prepared for investment committee review.

Scope
Two ventures, technical and financial
Output
10-year P&L, CAPEX recovery, IRR and profit-split structures
Outcome
Issued for investor decision
3.0

Standards worked to

Regulatory

  • 21 CFR 210, 211CGMP for finished pharmaceuticals
  • 21 CFR Part 11Electronic records and signatures
  • EU GMPParts I and II, Chapter 2 — personnel and training
  • EU GMP Annex 1Sterile medicinal products
  • WHO GMPGood manufacturing practices for pharmaceutical products
  • Schedule MDrugs and Cosmetics Rules, India
  • ICH Q1Stability testing
  • ICH Q2(R2)Analytical procedure validation
  • ICH Q3A–CImpurities in substances and products
  • ICH Q3DElemental impurities
  • ICH Q6ASpecifications
  • ICH Q7GMP for active pharmaceutical ingredients
  • ICH Q8Pharmaceutical development
  • ICH Q9Quality risk management
  • ICH Q10Pharmaceutical quality system
  • ICH Q14Analytical procedure development
  • ICH M7Mutagenic impurities, including NDSRI

Management systems and laboratory

  • ISO 9001Quality management
  • ISO 13485Medical devices
  • ISO 14001Environmental management
  • ISO 17025Testing and calibration laboratories
  • ISO 17034Reference material producers
  • ISO 45001Occupational health and safety
  • HBELHealth-based exposure limits
  • MACOCleaning validation limits
  • BEBioequivalence study design and review
4.0

Principal consultant

Dr. Subhash Kale

M.Sc. · Ph.D. · MBA · PGDRA
ISO 9001 Lead Auditor

Thirty-one years in Indian pharmaceutical manufacturing across quality assurance, regulatory affairs, CMC and analytical sciences, before founding Einstein Pharma Consultancy Services.

The method is consistent across every engagement: read what the regulator actually wrote, identify the system that failed rather than the person or the batch, and document the correction so that it holds up when someone independent reviews it two years later.

Engagements are taken on a defined scope with a defined deliverable. Where an investigation is likely to reach an uncomfortable conclusion, that conclusion is written down.

5.0

Experience

Indian pharmaceutical industry

Career across 31 years

  • Lupin
  • Unichem
  • FDC
  • Strides Pharma
  • HPPL
  • Micro Labs
  • Wockhardt R&D
  • Galentic
  • Mac-Chem

Collaborative project work

Projects delivered in collaboration with

  • Hospira
  • Baxter
  • GSK
  • Aspen
  • Chanelle
  • Thermo Fisher
  • Avantor

Consultancy clients

Einstein Pharma Consultancy Services

  • Medley Pharma
  • OM Pharma
  • JAYCO Pharma
  • Chemnovo Synthesis
  • Pallav Chemicals
  • Rivine Industries
  • Shreeshail Laboratories
Associate

DSK Life Sciences Academy

Our training arm for pharmaceutical professionals — practical courses in quality assurance, regulatory affairs and analytical sciences, built on real FDA cases and inspection findings. Founded and mentored by Dr. Subhash Kale.

Visit dsklsa.com →
6.0

Describe the problem. We will tell you whether we are the right people.

Most engagements begin with a document — a deficiency letter, an observation, a protocol under challenge. Send it, or describe the situation, and you will get an honest view of scope and whether it is worth taking further.

Mobile
+91 98920 27657
Email
[email protected]
Address
Flat No. 202, Jai Gurudev CHS
Plot No. 6, Sector 1, Off Palm Beach Road
Sanpada, Navi Mumbai – 400 705
Maharashtra, India
View on map
Principal Consultant
Dr. Subhash Kale
GSTIN
27ACGPK4109C1Z1
Scan to save contact